Option chain shows key data for Atara Biotherapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Atara Biotherapeutics.

Atara Biotherapeutics (NASDAQ:ATRA) Stock, Option Chain

ATARA BIOTHERAPEUTICS INC

Atara Biotherapeutics

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Biotech

News

Health Care

Movers

Trading Ideas

General

ATRA

FDA halts Atara&#39;s EBVALLO and ATA3219 trials over manufacturing issues. Atara eyes $60 million milestone from Pierre Fabre upon EBVALLO approval.

FDA Places Clinical Hold On Atara Biotherapeutics&#39; Two Cell Therapy Programs

5 Retail Stocks Morgan Stanley Says Are Leading The Pack This Holiday Season

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

BMRA

DOYU

LFLY

PSNY

Nasdaq Down 150 Points; Morgan Stanley Earnings Top Estimates

Crude-oil-4-logo

SEZL

Crude Oil Down 1%; Bank of America Posts Upbeat Earnings

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics Inc

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA

ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Legal

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress

Agenus

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Annovis Bio

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

bluebird bio

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

Celularity

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Dyadic International, Inc. - Common Stock

Dyadic International

FibroBiologics

Forte Biosciences

FibroGen

ImmuCell

Kala Bio

Lantern Pharma

MAIA Biotechnology

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Rein Therapeutics

RenovoRx

Surrozen

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

Xilio Therapeutics

Canaccord Genuity

Rodman & Renshaw

Mizuho

Goldman Sachs

Stifel

Comments

Atara Biotherapeutics

Atara Biotherapeutics (ATRA) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga